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Background: Pulmonary thromboembolism (PTE) occurs in a wide variety of clinical
settings and presents a diagnostic challenge to clinicians, often requiring extensive
imaging of the vascular bed. Management increasingly requires accurate risk
stratification to rapidly identify those with massive and submassive PTE requiring
different therapeutic strategies such as thrombolysis. Provision of a rapid blood test
that improves diagnostic certainty and helps stratify risk could therefore bridge the
gap between uncertainty and delivery of immediate early life-saving treatment.
Methods and results: One hundred and fourteen consecutive patients with
suspected PTE underwent prospective evaluation. Venous blood samples were
obtained from an unselected group referred for ventilation–perfusion scintigraphy.
B-type natriuretic peptide (BNP), atrial natriuretic peptide (ANP) and N-terminal
pro-ANP (N-ANP) were measured by radioimmunoassay using commercially available
kits. The scans were classified into three groups according to standard criteria
(PIOPED); normal scan (N) (n ¼ 20), low/intermediate probability (L=I) of PTE
(n ¼ 77) and high probability (H) of PTE (n ¼ 17). Comparisons were also made
between patients with high probability scans who died (n ¼ 3) and those who
survived (n ¼ 14). Values are quoted for the median and interquartile ranges. There
were statistically significant differences between groups for levels of (a) BNP
(Po0:001): N ¼ 6.7 pmol/l (5.6–11.9), L/I ¼ 12.5 pmol/l (6.7–28.2) and
H ¼ 18.5 pmol/l (12.6–74.6); (b) ANP (Po0:005): N ¼ 12.6 pmol/l (7.1–16.0),
L=I ¼ 19.51 pmol/l (12.5–28.2) and H ¼ 19.1 pmol/l (15.7–31.7) and (c) N-ANPElsevier Ltd. All rights reserved.
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Natriuretic peptides in pulmonary embolism 1287(Po0:05): N ¼ 177 pmol/l (119–200), L/I ¼ 302 pmol/l (152–576) and H ¼ 322 pmol/
l (223–563). Levels of BNP and ANP were significantly (Po0:05) higher in patients
with high probability scans and a diagnosis of PTE who died (n ¼ 3) than in those who
survived (n ¼ 14); BNP: 91.6 pmol/l (77.5–336.2) vs. 14.4 pmol/l (11.9–27.4) and
ANP 32.5 pmol/l (21.7–105.5) vs. 17.6 pmol/l (15.2–19.3), respectively.
Conclusions: PTE is associated with significantly elevated levels of the natriuretic
peptides ANP, BNP and N-ANP. Increasing ventilation–perfusion mismatch on
scintigraphy corresponds to incremental increases in the levels of ANP, BNP and N-
ANP found. These peptides, and in particular BNP, may add to the diagnosis by
rapidly providing a probability of PE before dedicated imaging studies can be
performed. Natriuretic peptides require further study to establish their role in
identifying a high-risk group who may benefit from early treatments such as
thrombolysis.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Pulmonary thromboembolism (PTE) occurs in a wide
variety of clinical settings and presents a diagnostic
challenge to clinicians often requiring extensive
imaging of the vascular bed. Clinical signs are often
non-specific, and early treatment relies on limited
information pending definitive testing with the
consequences are of a condition that is both over-
and underdiagnosed.1
Recently there has been much interest in a family
of peptides known as natriuretic peptides in the
diagnosis and risk stratification of conditions such
as heart failure. Atrial natriuretic peptide (ANP)
and B-type natriuretic peptide (BNP) are hormones
released by myocardial stretch2 and have been
shown to be sensitive markers of left ventricular
systolic dysfunction;3,4 an inactive N-terminal
fragment (N-ANP) is also released. Their physiolo-
gical role mediates natriuresis and vasodilatation
through cGMP activation.2 The natriuretic peptides
are also elevated in pulmonary disease with acute
hypoxaemia5 or cor pulmonale, and increase in
proportion to the degree of right ventricular
dysfunction.
PTE can present as a life threatening illness
typically with signs of right ventricular dysfunction
or haemodynamic instability. Thrombolysis benefits
this subgroup specifically,6 but an unacceptable risk
of haemorrhage arises if thrombolysis is adminis-
tered to patients with no evidence of massive
or sub-massive PTE. There is a need to define the
risk of pulmonary embolus early, and identify
the subgroup of patients that may benefit from
immediate thrombolysis or transfer to a higher
level of care. Provision of a rapid blood test
that improves diagnostic certainty and helps
stratify risk could therefore bridge the gap
between uncertainty and delivery of early life-
saving treatment.Thus there is a rationale within the natural
history of acute PTE, that natriuretic peptides may
be released with increasing right ventricular after-
load, associated with significant territory occlusion
of the vascular bed. This is supported by the finding
of isolated case reports of elevated BNP levels in
patients with PTE7 and the finding of increased
mortality with raised BNP levels for those with
acute pulmonary embolism.8 We hypothesised that
natriuretic peptides may rise in PTE and in
addition, provide a rapid, early indicator of the
risk of associated right ventricular dysfunction and
death.Patients and methods
Subjects
One hundred and fourteen unselected, consecutive
patients (age range 20–91 years) undergoing in-
vestigation for suspected pulmonary embolism
were recruited into the study over 3 months. The
Tayside Committee for Medical Research Ethics
approved the study and all patients gave informed
written consent prior to inclusion. All eligible
patients were referred by their primary physician
with clinical suspicion of PTE for investigation at
their local teaching hospital. Patients were not
excluded from the study even with conditions
known to independently increase natriuretic pep-
tides such as left ventricular dysfunction. Many of
these conditions are independent risk factors for
PTE mortality and exclusion may therefore have
introduced selection bias. Therefore, echocardio-
graphy was not performed in our patient population
as a routine investigation primarily to prevent such
selection bias and to include a representative
cohort of patients referred with suspected PTE.
Patient characteristics are shown in Table 1.
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Table 1 Characteristics of 114 participants.
Characteristic Probability of PE as defined by V/Q scan result
Normal Low/Intermediate High
Number 20 77 17
Age (years) 46718 64715 69711
Male (%) 25 39 65
Impaired LV function 1 6 3
PPH 0 2 1
Creatinine4120mmol/l 2 14 4
COPD 0 18 1
Age is expressed as mean7standard deviation. PPH, primary pulmonary hypertension; COPD, chronic obstructive pulmonary
disease.
D.G. Kiely et al.1288Radionuclide scan
Each patient underwent radionuclide scanning in
the investigation of PTE in addition to other
diagnostic modalities. The same experienced radi-
ologist, blinded to the values of natriuretic
peptides, reported all radionuclide scans. On
completion each scan was classified into one of
three validated groups (normal, high, and a third
group including patients with a low or intermediate
probability of Pte) according to the findings of the
PIOPED study.9,10
Natriuretic peptide assay
Venous blood was taken in the prone position at the
same time as the perfusion scan was performed,
prior to injection of Tc labelled MAA. ANP, brain
natriuretic peptide (BNP) and N-terminal pro atrial
natriuretic peptide (N-ANP) levels were assessed by
radioimmunoassay (Peninsula Laboratories, St.
Helens, UK).
Data analysis
The individual data points for levels of natriuretic
peptides in patients with normal, high probability
and low/intermediate probability scans are repre-
sented in dot plots. Comparisons between these
groups were made using the non-parametric Krus-
kal–Wallis test. Comparisons between levels of
natriuretic peptides in patients with high prob-
ability scans who were alive on discharge or died
during their hospital admission were made using
the non-parametric Mann–Witney U-test. A two
tailed probability of Po0:05 was considered to be
statistically significant. Values are quoted as
median and interquartile ranges.Results
The study group consisted of 114 consecutive
patients who underwent radionuclide scanning. Of
these, 20 were reported as normal, 77 as repre-
senting low or intermediate probability of pulmon-
ary embolism and 17 representing a high probability
of PTE. All patients with high probability scans
according to PIOPED criteria also had a clinical
diagnosis of PTE and were anticoagulated.
Figure 1 demonstrates the results of natruiretic
peptide assay in patients with normal, intermedi-
ate and high probability scans. Values are quoted
for the median and interquartile ranges. There
were statistically significant differences between
groups for levels of (a) BNP (Po0:001): N ¼
6.7 pmol/l (5.6–11.9), L/I ¼ 12.5 pmol/l (6.7–28.2)
and H ¼ 18.5 pmol/l (12.6–74.6); (b) ANP (Po
0:005): N ¼ 12.6 pmol/l (7.1–16.0), L/I ¼ 19.51
pmol/l (12.5–28.2) and H ¼ 19.1 pmol/l (15.7–
31.7) and (c) N-ANP (Po0:05): N ¼ 177 pmol/l
(119–200), L/I ¼ 302 pmol/l (152–576) and H ¼
322 pmol/l (223–563).
There were three deaths in the study, each with a
high probability radionuclide scan. Levels of BNP
and ANP were significantly (Po0:05) higher in
patients with high probability scans who died from
pulmonary embolism than in those who survived;
BNP: 91.6 pmol/l (77.5–336.2) vs. 14.4 pmol/l
(11.9–27.4) and ANP: 32.5 pmol/l (21.7–105.5) vs.
17.6 pmol/l (15.2–19.3) (Fig. 2).Discussion
This study is the first to report elevated levels of
the natriuretic peptides ANP, BNP and N-ANP
in patients with high probability of PTE on
radionuclide scanning. In addition, we have
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Figure 1 The individual data points for levels of
natriuretic peptides atrial natriuretic peptide (ANP), B-
type natriuretic peptide (BNP) and N-terminal proatrial
natriuretic peptide (N-ANP) in patients with normal (N),
high probability (H) and low/intermediate probability
scans (L/I) are represented in dot plots.
Figure 2 Comparisons between levels of natriuretic
peptides atrial natriuretic peptide (ANP), B-type na-
triuretic peptide (BNP) and N-terminal proatrial natriure-
tic peptide (N-ANP) in patients with high probability
scans who were alive on discharge or died during their
hospital admission.
Natriuretic peptides in pulmonary embolism 1289demonstrated a significant relationship between
elevated levels of ANP and BNP in patients with high
probability scans and a clinical diagnosis of PTE who
died compared to survivors.
Natriuretic peptides are thought to be released
as a consequence of a stretch coupling mechanism
and are elevated in a number of conditions
characterised by elevations in left and right atrial
and ventricular pressures such as left ventricular
failure,2–4 hypoxaemic cor pulmonale11 and pri-mary pulmonary hypertension.12 It is also known
that acute hypoxia is a potent stimulus to ANP but
not BNP13 secretion and the hypoxaemia seen in
patients with pulmonary embolism may have con-
tributed to elevated levels of ANP. We have also
shown that levels of the inactive N-terminal portion
of the 126 amino acid prohormone of ANP, N-ANP
are elevated.14 The natriuretic peptides may be
released in an attempt to improve haemodynamic
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D.G. Kiely et al.1290function by triggering vasodilatation and natriur-
esis.15,16 Previously there have isolated reports of
elevated plasma BNP associated with acute pul-
monary embolismin patients with RV dysfunc-
tion;8,17 ANP and BNP levels are also elevated in
asymptomatic patients with chronic right ventricu-
lar pressure overload caused by congenital heart
disease.18
As well as the finding of elevated levels of ANP,
BNP and N-ANP in patients with high probability of
PTE, there is a progressive incremental rise in
natriuretic peptide levels with increasing degrees
of ventilation–perfusion mismatch within the lung,
suggestive of a direct relationship between perfu-
sion defects and release of natriuretic peptide. The
levels of ANP, BNP and N-ANP all correlate strongly
together in subjects with suspected pulmonary
embolism, supportive of the notion that the
development of ventilation–perfusion defects sti-
mulates natriuretic peptide release from the
myocardium by cardiac myocyte stretch.
The patients who died with pulmonary embolus
had significantly elevated levels of natriuretic
peptides compared to survivors. Levels of BNP in
patients with high probability scans who died were
15–100 times greater than the upper limit of
normal. BNP release from the right ventricle5 in
PTE may aid early risk stratification, given that BNP
can be assayed rapidly in the emergency depart-
ment19 and acute right ventricular dysfunction is a
major determinant of outcome of acute PE in
hospital.20 Indeed, RV dysfunction defined echo-
cardiographically has recently identified a group of
patients with an adverse prognostic risk likely to
benefit from thrombolysis.6,21 The finding of a
statistically significant increase in mortality asso-
ciated with high BNP levels leads to the speculation
that higher BNP levels are therefore associated
with an increased risk of death though admittedly
the numbers of deaths in the study group were
small. For those with major pulmonary emboli and
haemodynamic compromise mortality is greatly
elevated with the majority of deaths occurring
within the first hour of presentation requiring
optimal diagnosis and therapy within one hour.22
We speculate that since BNP measurement is
rapidly available and non-invasive, it may be a
useful tool in the risk stratification of patients with
suspected pulmonary embolus.
This study is limited primarily by the diagnostic
tool commonly used in the diagnosis of PTE namely,
ventilation–perfusion (V/Q) scanning. It seems
reasonable to suppose that in those with a high
pre-test clinical probability of PTE, combined with
a high probability V/Q scan had pulmonary emboli
according to validated criteria from the PIOPEDstudy. The PIOPED study demonstrated that for
patients with normal or high probability lung scans,
a diagnosis of PTE can be refuted or confirmed with
a high degree of probability, and that these
probabilities can be refined further by using clinical
probabilities. In patients with low or intermediate
probability lung scan results V/Q scanning is much
less helpful and clinical probabilities become more
useful, we have categorised this group as a single
cohort
’ ’
intermediate probability’’. Due to inac-
curacies in the phenotype of this group (who are
likely to contain patients with and without PTE)
due to assumptions regarding clinical diagnosis
given by the individual clinicians for these patients,
with or without performing further investigation,
we have not tried to characterise these patients
further. Fig. 1 demonstrates that for normal
probability scans that there is a large spread of
values suggesting that the test is not specific
enough to obviate the need for additional investi-
gation for PTE.
What are the possible clinical applications of our
results? Measurement of natriuretic peptides such
as BNP may aid clinical decision making in diagnosis
and rapid risk stratification of PTE. Natriuretic
peptide levels may also help identify differential
diagnoses such as left ventricular failure3,4 in which
there is an increased mortality associated with the
development of acute PTE.23 This pilot study
suggests that further work is required to establish
the utility of this peptide family in PTE and whether
it will help to reduce excess mortality in a
previously unidentified high-risk group.Acknowledgements
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